Efficacy and Safety of Oral HBI-8000 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

NCT02953652 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

55

Enrollment

INDUSTRY

Sponsor class

Conditions

Peripheral T-Cell Lymphoma (PTCL)

Interventions

DRUG: HBI-8000

Sponsor

HUYABIO International, LLC.

Collaborators

[object Object]